Soru

Zorluk: OrtaEndocrine and Metabolic Mechanisms

A 58-year-old man with a 10-year history of type 2 diabetes mellitus is brought to the emergency department by his wife due to severe nausea, vomiting, and generalized weakness for the past 48 hours. He recently had a viral upper respiratory infection and has had poor oral intake. His medications include metformin, empagliflozin, and lisinopril. Vital signs show a blood pressure of 98/6298/62 mmHg, heart rate of 115115/min, and respiratory rate of 2424/min. Physical examination reveals dry mucous membranes.

Laboratory studies show:

Laboratory TestResultReference Range
Serum sodium136136 mEq/L136−145136-145 mEq/L
Serum potassium4.84.8 mEq/L3.5−5.03.5-5.0 mEq/L
Serum chloride102102 mEq/L95−10595-105 mEq/L
Serum bicarbonate1212 mEq/L22−2822-28 mEq/L
Blood urea nitrogen3434 mg/dL7−187-18 mg/dL
Serum creatinine1.61.6 mg/dL0.6−1.20.6-1.2 mg/dL
Serum glucose178178 mg/dL70−11070-110 mg/dL
Serum ketonesPositiveNegative

Arterial blood gas analysis reveals a pH of 7.247.24.

Which of the following is the most direct underlying metabolic mechanism precipitating this patient's primary acid-base disturbance?

  1. Increased ratio of circulating glucagon to insulinCevap
  2. B
    Inhibition of mitochondrial glycerophosphate dehydrogenase
  3. C
    Complete cessation of endogenous pancreatic insulin secretion
  4. D
    Decreased renal tubular excretion of unmeasured organic anions
  5. E
    Decreased aldosterone synthesis resulting in impaired distal tubular acid secretion

Cevap

Increased ratio of circulating glucagon to insulin
The patient presents with a high anion-gap metabolic acidosis (136−102−12=22136 - 102 - 12 = 22 mEq/L) and positive serum ketones, diagnostic of diabetic ketoacidosis (DKA). However, his blood glucose is unexpectedly low for standard DKA presentation (178178 mg/dL). This presentation is characteristic of euglycemic DKA, a known, life-threatening adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors like empagliflozin. SGLT2 inhibitors block proximal tubular glucose reabsorption, resulting in massive, continuous glycosuria. This artificially lowers serum glucose, which in turn decreases pancreatic beta-cell insulin secretion and strongly stimulates alpha-cell glucagon release. The resulting high glucagon-to-insulin ratio promotes severe lipolysis, releasing free fatty acids that undergo hepatic oxidation into ketone bodies. The physiologic stress of his recent viral infection and subsequent poor oral intake further exacerbated this dangerous glucagon-heavy metabolic state.

Adım Adım Çözüm

1
Calculate the serum anion gap to classify the primary acid-base disturbance.
Anion gap = 136−(102+12)=22136 - (102 + 12) = 22 mEq/L.
An elevated anion gap (>12>12 mEq/L) restricts the differential diagnosis to specific causes such as ketoacidosis, lactic acidosis, uremia, or toxin ingestion.
2
Correlate the high anion gap with the patient's specific lab findings and medication history.
The patient has positive serum ketones but a relatively normal blood glucose level (178178 mg/dL) while actively taking an SGLT2 inhibitor (empagliflozin).
Positive ketones confirm ketoacidosis. The absence of marked hyperglycemia (glucose <250<250 mg/dL) points to euglycemic diabetic ketoacidosis, a classic complication of SGLT2 inhibitors.
3
Identify the primary cellular and hormonal mechanism of SGLT2 inhibitor-induced euglycemic ketoacidosis.
SGLT2 inhibitors cause profound urinary glucose loss, decreasing blood glucose levels, which subsequently decreases insulin secretion and drastically increases glucagon secretion.
The resulting high glucagon-to-insulin ratio directly stimulates hepatic lipid oxidation and ketogenesis, causing the profound ketoacidosis seen in the presentation.

Anahtar Kavram

Sodium-glucose cotransporter-2 (SGLT2) inhibitors can precipitate euglycemic diabetic ketoacidosis by inducing profound glycosuria, creating a state of relative insulin deficiency and marked glucagon excess that drives ketogenesis.
Bu soruyu puanla